Myasthenia-like syndrome associated with carnitine in patients on long-term haemodialysis
It makes you human, dealing with a complex metabolic condition that GLP-1 medications manage but do not cure
Faster Recovery and Reduced Inflammation IGF-1 plays a critical role in musculoskeletal healing , including tendon, ligament, and muscle repair

Baseline bloodwork CBC, CRP, ferritin, IL-6, cortisol AM, metabolic panel, thyroid function Cardiovascular assessment heart rate variability, orthostatic vitals if POTS is suspected Gut health markers stool testing, zonulin, calprotectin if GI symptoms are prominent Mitochondrial function proxies lactate, organic acids panel if PEM is a primary complaint From there, a typical protocol might be structured as: Phase 1 (Weeks 16): Immune and gut foundation Thymosin Alpha-1: 1.6 mg subcutaneous, twice weekly BPC-157: 250500 mcg daily, route determined by predominant symptom (oral for gut, injectable for systemic) Phase 2 (Weeks 412): Tissue repair and cardiovascular recovery TB-500: 2.02.5 mg subcutaneous, twice weekly Continue BPC-157 as indicated Phase 3 (Weeks 816): Maintenance and metabolic support Taper or pulse doses based on clinical response Add mitochondrial support if fatigue persists (see: Mitochondrial Peptides and Insulin Resistance) These are illustrative dosing ranges based on clinical research and published protocols

This may expand the options available to patients for breast cancer prevention, particularly for women for whom current preventive medications are unsuitable
The cost difference can exceed 3,000 per year